Claims for Patent: 9,809,559

Summary for Patent: 9,809,559

Title:	(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Abstract:	The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Inventor(s):	Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
Assignee:	GlaxoSmithKline LLC
Application Number:	US15/231,411
Patent Claims:	1. A method of treating myelofibrosis or polycythemia vera comprising administering to a subject in need thereof a compound selected from the group consisting of: N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form I; and N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III. 2. The method of claim 1, wherein the compound is in a crystalline form. 3. The method of claim 2, wherein the crystalline form is N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II. 4. The method of claim 3, wherein the crystals have unit cell parameters at T=100° K of: a=10.2837(6) Å, b=10.4981(6) Å, c=11.5143(7) Å, α=83.297(2)°, β=87.649(2)°, γ=67.445(2)°, and a triclinic P-1 space group. 5. The method of claim 3, wherein the crystalline form is characterized by an x-ray powder diffraction (XRPD) pattern substantially as set forth in FIG. 5. 6. The method of claim 3, wherein the crystalline form is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at about 7.7°, 19.3°, 24.0°, 25.7°, and 29.6° 2-θ±0.2° 2-θ. 7. The method of claim 3, wherein the crystalline form is characterized by differential scanning calorimetry (DSC) pattern substantially as set forth in FIG. 8. 8. The method of claim 3, wherein the crystalline form is characterized by a dynamic vapor sorption (DVS) pattern substantially as set forth in FIG. 14. 9. The method of claim 2, wherein the crystalline form is crystalline N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form I. 10. The method of claim 9, wherein the crystalline form is characterized by an x-ray powder diffraction (XRPD) pattern substantially as set forth in FIG. 6. 11. The method of claim 9, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern having peaks at about 13.5°, 20.9°, 26.1°, 26.6°, and 28.3° 2-θ±0.2° 2-θ. 12. The method of claim 9, wherein the crystalline form is characterized by a differential scanning calorimetry (DSC) pattern substantially as set forth in FIG. 9. 13. The method of claim 2, wherein the crystalline form is crystalline N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III. 14. The method of claim 13, wherein the crystalline form is characterized by an x-ray powder diffraction (XRPD) pattern substantially as set forth in FIG. 7. 15. The method of claim 13, wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern having peaks at about 12.7°, 14.6°, 17.8°, 19.7°, and 23.3° 2-θ±0.2° 2-θ. 16. The method of claim 13, wherein the crystalline form is characterized by a differential scanning calorimetry (DSC) pattern substantially as set forth in FIG. 10.